QLGN vs. KPRX, KLTO, JAGX, BCLI, PHXM, CSCI, AIMD, AEON, RLMD, and TSBX
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include Kiora Pharmaceuticals (KPRX), Klotho Neurosciences (KLTO), Jaguar Health (JAGX), Brainstorm Cell Therapeutics (BCLI), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), Ainos (AIMD), AEON Biopharma (AEON), Relmada Therapeutics (RLMD), and Turnstone Biologics (TSBX). These companies are all part of the "pharmaceutical products" industry.
Qualigen Therapeutics vs.
Qualigen Therapeutics (NASDAQ:QLGN) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, community ranking, risk and institutional ownership.
3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.9% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Qualigen Therapeutics. Qualigen Therapeutics' average media sentiment score of 0.00 equaled Kiora Pharmaceuticals'average media sentiment score.
Kiora Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 188.18%. Given Kiora Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Qualigen Therapeutics.
Qualigen Therapeutics has a beta of -0.68, indicating that its share price is 168% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500.
Kiora Pharmaceuticals' return on equity of 21.32% beat Qualigen Therapeutics' return on equity.
Kiora Pharmaceuticals has lower revenue, but higher earnings than Qualigen Therapeutics.
Kiora Pharmaceuticals received 10 more outperform votes than Qualigen Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Qualigen Therapeutics an outperform vote while only 73.91% of users gave Kiora Pharmaceuticals an outperform vote.
Summary
Kiora Pharmaceuticals beats Qualigen Therapeutics on 11 of the 14 factors compared between the two stocks.
Get Qualigen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:QLGN) was last updated on 2/22/2025 by MarketBeat.com Staff
